

Harry Sokol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3791009/publications.pdf>

Version: 2024-02-01

256
papers

30,597
citations

7568

77
h-index

5255

165
g-index

275
all docs

275
docs citations

275
times ranked

29348
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of adherent and invasive <i>Escherichia coli</i> in Crohn's disease: lessons from the postoperative recurrence model. <i>Gut</i> , 2023, 72, 39-48.	12.1	22
2	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms. <i>Gut Microbes</i> , 2022, 14, 2022997.	9.8	19
3	Evolution of FMT “ From early clinical to standardized treatments. <i>Biologicals</i> , 2022, , .	1.4	3
4	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1269-1280.	1.3	15
5	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases. <i>Neurogastroenterology and Motility</i> , 2022, , e14320.	3.0	2
6	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 2116-2125.	2.9	7
7	Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea. <i>BMC Microbiology</i> , 2022, 22, 54.	3.3	1
8	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. , 2022, 1, 393-402.		3
9	Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. <i>Journal of Crohn's and Colitis</i> , 2022, , .	1.3	3
10	Gut Microbiota Reprogramming of Tryptophan Metabolism During Pregnancy Shapes Host Insulin Resistance. <i>Gastroenterology</i> , 2022, , .	1.3	2
11	Microbiota in Neuroinflammation and Synaptic dysfunction: a focus on Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 19.	10.8	89
12	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. <i>Gut Microbes</i> , 2022, 14, 2018900.	9.8	47
13	Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers—Example of Crohn's Disease and Ulcerative Colitis Flare-Ups. <i>Cells</i> , 2022, 11, 1340.	4.1	11
14	Human CD4 ⁺ CD8 ⁺ Tregs induced by <i>Faecalibacterium prausnitzii</i> protect against intestinal inflammation. <i>JCI Insight</i> , 2022, 7, .	5.0	23
15	SER-109 for Recurrent <i>Clostridioides difficile</i> Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1956-1958.	27.0	1
16	On the Determinants of IDO Activity in Patients With Familial Mediterranean Fever. <i>Modern Rheumatology</i> , 2022, , .	1.8	0
17	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. <i>Gut Microbes</i> , 2022, 14, .	9.8	20
18	Deletion of both Dectin-1 and Dectin-2 affects the bacterial but not fungal gut microbiota and susceptibility to colitis in mice. <i>Microbiome</i> , 2022, 10, .	11.1	7

#	ARTICLE	IF	CITATIONS
19	Alteration of the gut microbiota's composition and metabolic output correlates with COVID-19-like severity in obese NASH hamsters. <i>Gut Microbes</i> , 2022, 14, .	9.8	8
20	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1602-1610.e1.	4.4	26
21	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. <i>Journal of Clinical Immunology</i> , 2021, 41, 185-193.	3.8	15
22	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021, 9, 229-247.	3.8	66
23	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. <i>Gut</i> , 2021, 70, 1299-1308.	12.1	92
24	Tryptophan Metabolism as a Pharmacological Target. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 60-73.	8.7	135
25	Gut microbiota-derived metabolites as central regulators in metabolic disorders. <i>Gut</i> , 2021, 70, 1174-1182.	12.1	519
26	Tryptophan metabolites get the gut moving. <i>Cell Host and Microbe</i> , 2021, 29, 145-147.	11.0	22
27	PRODICE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.9	10
28	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	8.1	5
29	Recipient factors in faecal microbiota transplantation: one stool does not fit all. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 503-513.	17.8	74
30	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. <i>Mucosal Immunology</i> , 2021, 14, 1127-1132.	6.0	9
31	Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal T _H 17 cells. <i>Cell Reports</i> , 2021, 36, 109332.	6.4	114
32	Butyrate, a new microbiota-dependent player in CD8 ⁺ T cells immunity and cancer therapy?. <i>Cell Reports Medicine</i> , 2021, 2, 100328.	6.5	19
33	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100181.	5.6	43
34	Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. <i>BMC Nutrition</i> , 2021, 7, 38.	1.6	8
35	Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. <i>Microbiome</i> , 2021, 9, 176.	11.1	22
36	Postbiotics "when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 825-826.	17.8	63

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCO 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.9	5
38	Osteoarthritis and gut microbiome. <i>Joint Bone Spine</i> , 2021, 88, 105203.	1.6	10
39	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. <i>Gut Microbes</i> , 2021, 13, 1-19.	9.8	75
40	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	30
41	Circulating bile acids concentration is predictive of coronary artery disease in human. <i>Scientific Reports</i> , 2021, 11, 22661.	3.3	22
42	Reporting guidelines for human microbiome research: the STORMS checklist. <i>Nature Medicine</i> , 2021, 27, 1885-1892.	30.7	170
43	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 141-149.e2.	4.4	32
44	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. <i>Gut</i> , 2020, 69, 462-472.	12.1	76
45	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 92-102.	12.1	136
46	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 620-627.e1.	4.4	21
47	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 150-157.e1.	4.4	23
48	Gut microbiota in PSC: From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., <i>Nature Microbiology</i> , January 2019. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 123-125.	1.5	3
49	Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 153-154.	3.7	1
50	The enemy from within: a prophage of <i>Roseburia intestinalis</i> systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. <i>ISME Journal</i> , 2020, 14, 771-787.	9.8	48
51	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 342-350.	1.3	2
52	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. <i>United European Gastroenterology Journal</i> , 2020, 8, 303-313.	3.8	79
53	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	3.7	30
54	Butyrate mediates anti-inflammatory effects of <i>Faecalibacterium prausnitzii</i> in intestinal epithelial cells through <i>Dact3</i> . <i>Gut Microbes</i> , 2020, 12, 1826748.	9.8	90

#	ARTICLE	IF	CITATIONS
55	Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. Clinical and Translational Medicine, 2020, 10, e163.	4.0	5
56	Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. Trends in Pharmacological Sciences, 2020, 41, 900-908.	8.7	35
57	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, 2020, 12, .	12.4	98
58	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094690.	3.2	21
59	The Gut Microbiota at the Service of Immunometabolism. Cell Metabolism, 2020, 32, 514-523.	16.2	152
60	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. Gastroenterology, 2020, 159, 2193-2202.e5.	1.3	41
61	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. Cancer Immunology Research, 2020, 8, 1407-1425.	3.4	33
62	Antibiotics: a trigger for inflammatory bowel disease?. The Lancet Gastroenterology and Hepatology, 2020, 5, 956-957.	8.1	8
63	Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. United European Gastroenterology Journal, 2020, 8, 1145-1146.	3.8	1
64	Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. Alimentary Pharmacology and Therapeutics, 2020, 52, 303-310.	3.7	1
65	Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs. Drug Discovery Today, 2020, 25, 1575-1579.	6.4	4
66	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials, 2020, 21, 455.	1.6	4
67	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. United European Gastroenterology Journal, 2020, 8, 353-354.	3.8	0
68	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432.	8.1	108
69	Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation. Frontiers in Immunology, 2020, 11, 144.	4.8	33
70	Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. Genome Medicine, 2020, 12, 58.	8.2	33
71	Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. Cell Reports, 2020, 32, 107915.	6.4	113
72	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	12.1	110

#	ARTICLE	IF	CITATIONS
73	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 223-237.	17.8	893
74	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	1.3	12
75	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. <i>Microbiome</i> , 2020, 8, 12.	11.1	203
76	Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. <i>Science</i> , 2020, 368, 186-189.	12.6	80
77	Specific changes in faecal microbiota are associated with familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1398-1404.	0.9	18
78	Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. <i>Microbiome</i> , 2019, 7, 111.	11.1	50
79	Oral delivery of pancreatitis-associated protein by <i>Lactococcus lactis</i> displays protective effects in dinitrobenzenesulfonic acid-induced colitis model and is able to modulate the composition of the microbiota. <i>Environmental Microbiology</i> , 2019, 21, 4020-4031.	3.8	15
80	A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1161-1162.	9.1	8
81	PS-126-Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e78.	3.7	1
82	Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. <i>Frontiers in Immunology</i> , 2019, 10, 143.	4.8	72
83	Fecal Microbiota Transplantation for Ulcerative Colitis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2240.	7.4	6
84	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. <i>PLoS Genetics</i> , 2019, 15, e1008018.	3.5	35
85	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
86	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. <i>Haematologica</i> , 2019, 104, 1682-1688.	3.5	91
87	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. <i>Gut</i> , 2019, 68, 1961-1970.	12.1	35
88	The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 331-345.	17.8	226
89	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. <i>United European Gastroenterology Journal</i> , 2019, 7, 1408-1410.	3.8	15
90	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	12.1	290

#	ARTICLE	IF	CITATIONS
91	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	2.9	28
92	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68, 1504-1515.	12.1	202
93	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. Talanta, 2019, 195, 593-598.	5.5	33
94	The regenerating family member 3 β instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. Gut, 2019, 68, 1190-1199.	12.1	14
95	Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen. International Journal of Obesity, 2019, 43, 428-431.	3.4	19
96	The Gut Microbiome in Inflammatory Bowel Disease. , 2019, , 347-377.		0
97	Impact of Gut Mycobiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 194-194.	1.4	0
98	Beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 193-194.	17.8	30
99	Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunology, 2018, 11, 1024-1038.	6.0	326
100	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <sc>OBSERV</sc>â€<sc>IBD</sc> cohort. Alimentary Pharmacology and Therapeutics, 2018, 47, 485-493.	3.7	91
101	Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation. Mucosal Immunology, 2018, 11, 1181-1190.	6.0	29
102	Differences in epidemiological features between ulcerative colitis and Crohnâ€™s disease: The early life-programmed versus late dysbiosis hypothesis. Medical Hypotheses, 2018, 115, 19-21.	1.5	11
103	The microbiota: an underestimated actor in radiation-induced lesions?. Gut, 2018, 67, 1-2.	12.1	54
104	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 59-67.	4.4	52
105	Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes, 2018, 9, 131-142.	9.8	142
106	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. Gut, 2018, 67, 1836-1844.	12.1	38
107	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. Gut Microbes, 2018, 9, 55-60.	9.8	85
108	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	1.9	17

#	ARTICLE	IF	CITATIONS
109	Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. <i>Hepatology Communications</i> , 2018, 2, 1533-1549.	4.3	28
110	Inhibitory Effect of Ursodeoxycholic Acid on <i>Clostridium difficile</i> Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. <i>Frontiers in Microbiology</i> , 2018, 9, 2849.	3.5	11
111	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 924-932.	3.7	71
112	Expression of CCR6 and CXCR6 by Gut-Derived CD4 ⁺ /CD8 ⁺ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 1205-1217.	1.3	42
113	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0201991.	2.5	29
114	Enterobacteriaceae are essential for the modulation of colitis severity by fungi. <i>Microbiome</i> , 2018, 6, 152.	11.1	143
115	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. <i>PLoS ONE</i> , 2018, 13, e0202587.	2.5	43
116	Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. <i>Nature Medicine</i> , 2018, 24, 1113-1120.	30.7	193
117	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. <i>Cell Metabolism</i> , 2018, 28, 737-749.e4.	16.2	356
118	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	3.7	10
119	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. <i>Frontiers in Immunology</i> , 2018, 9, 1039.	4.8	6
120	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. <i>Frontiers in Microbiology</i> , 2018, 9, 565.	3.5	30
121	<i>Bilophila wadsworthia</i> aggravates high fat diet induced metabolic dysfunctions in mice. <i>Nature Communications</i> , 2018, 9, 2802.	12.8	317
122	Gut Microbiota-Stimulated Innate Lymphoid Cells Support β -Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. <i>Cell Metabolism</i> , 2018, 28, 557-572.e6.	16.2	84
123	Phages infecting <i>Faecalibacterium prausnitzii</i> belong to novel viral genera that help to decipher intestinal viromes. <i>Microbiome</i> , 2018, 6, 65.	11.1	98
124	Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. <i>Cell Host and Microbe</i> , 2018, 23, 716-724.	11.0	1,442
125	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , 2018, 14, e1007329.	3.5	66
126	Abstract 585: Card9 Deficiency Accelerates Experimental Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	2.4	0

#	ARTICLE	IF	CITATIONS
127	Fungal microbiota dysbiosis in IBD. <i>Gut</i> , 2017, 66, 1039-1048.	12.1	939
128	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	12.1	793
129	A microbial signature for Crohn's disease. <i>Gut</i> , 2017, 66, 813-822.	12.1	657
130	<i>Clostridium difficile</i> infection in acute flares of inflammatory bowel disease: A prospective study. <i>Digestive and Liver Disease</i> , 2017, 49, 643-646.	0.9	57
131	Caspase recruitment domain 9, microbiota, and tryptophan metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2017, 20, 243-247.	2.5	17
132	Inflammatory Bowel Diseases: How to Identify High-Risk Patients. , 2017, , 653-660.		0
133	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	3.7	128
134	Fecal Microbiota Transplantation: Do We Need Harmonization?. <i>Clinical Infectious Diseases</i> , 2017, 64, 1292-1292.	5.8	8
135	Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1614-1622.	0.9	266
136	Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. <i>Clinical Infectious Diseases</i> , 2017, 64, 767-775.	5.8	57
137	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017, 112, 337-345.	0.4	138
138	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	3.7	23
139	Microbiota in digestive cancers: our new partner?. <i>Carcinogenesis</i> , 2017, 38, 1157-1166.	2.8	14
140	Using murine colitis models to analyze probiotics' host interactions. <i>FEMS Microbiology Reviews</i> , 2017, 41, S49-S70.	8.6	47
141	The Presence of Adherent-Invasive <i>Escherichia Coli</i> (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S9.	1.3	1
142	Probiotic Strain <i>Lactobacillus casei</i> BL23 Prevents Colitis-Associated Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1553.	4.8	156
143	Functional Characterization of Novel <i>Faecalibacterium prausnitzii</i> Strains Isolated from Healthy Volunteers: A Step Forward in the Use of <i>F. prausnitzii</i> as a Next-Generation Probiotic. <i>Frontiers in Microbiology</i> , 2017, 8, 1226.	3.5	320
144	New Insights into the Diversity of the Genus <i>Faecalibacterium</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 1790.	3.5	71

#	ARTICLE	IF	CITATIONS
145	Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. PLoS ONE, 2017, 12, e0184624.	2.5	10
146	Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. Frontiers in Microbiology, 2016, 7, 608.	3.5	50
147	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS ONE, 2016, 11, e0157191.	2.5	19
148	Mature CD8 + T cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. Clinical Case Reports (discontinued), 2016, 4, 1088-1090.	0.5	1
149	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2402-2409.	1.9	143
150	1120 Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S225.	1.3	0
151	Mo1852 Impact of Fertility Treatment on Inflammatory Bowel Disease Outcomes. Gastroenterology, 2016, 150, S795.	1.3	0
152	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	4.4	168
153	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature Medicine, 2016, 22, 598-605.	30.7	1,001
154	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 44, 1102-1113.	3.7	42
155	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
156	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunology, 2016, 9, 1360-1365.	6.0	64
157	Editorial: mongersen in Crohn's disease "a new contribution to the beginning of a long-awaited therapeutic revolution?". Alimentary Pharmacology and Therapeutics, 2016, 43, 838-839.	3.7	0
158	Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific Reports, 2016, 6, 18507.	3.3	174
159	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Scientific Reports, 2016, 6, 19399.	3.3	72
160	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 416-420.	5.7	4
161	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 1330-1340.	3.0	103
162	Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut, 2016, 65, 415-425.	12.1	585

#	ARTICLE	IF	CITATIONS
163	Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 375-376.	1.3	9
164	The presence of the anti-inflammatory protein MAM, from <i>Faecalibacterium prausnitzii</i> , in the intestinal ecosystem. <i>Gut</i> , 2016, 65, 882.1-882.	12.1	32
165	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 296-305.	1.3	252
166	Identification of novel anti-inflammatory probiotic strains isolated from pulque. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 385-396.	3.6	54
167	Faecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection: Recommendations from the French Group of Faecal microbiota Transplantation. <i>Digestive and Liver Disease</i> , 2016, 48, 242-247.	0.9	53
168	Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. <i>ISME Journal</i> , 2016, 10, 460-477.	9.8	100
169	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. <i>Digestive Diseases</i> , 2015, 33, 105-112.	1.9	28
170	Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 349-355.	1.3	16
171	Inflammatory bowel disease after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1365-1366.	2.4	6
172	Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of <i>Faecalibacterium prausnitzii</i> . <i>MBio</i> , 2015, 6, .	4.1	206
173	<i>Faecalibacterium prausnitzii</i> prevents physiological damages in a chronic low-grade inflammation murine model. <i>BMC Microbiology</i> , 2015, 15, 67.	3.3	208
174	<i>Lactobacillus rhamnosus</i> CNCM I-3690 and the commensal bacterium <i>Faecalibacterium prausnitzii</i> A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. <i>Gut Microbes</i> , 2015, 6, 1-9.	9.8	143
175	Gut Fungal Microbiota. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 656-665.	1.9	93
176	Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 60-70.	1.9	34
177	Changes in the LÃ©mann Index Values During the First Years of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1633-1640.e3.	4.4	47
178	Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. <i>Cell Metabolism</i> , 2015, 22, 460-471.	16.2	107
179	An Image-Based Genetic Assay Identifies Genes in T1D Susceptibility Loci Controlling Cellular Antiviral Immunity in Mouse. <i>PLoS ONE</i> , 2014, 9, e108777.	2.5	6
180	Effects in the use of a genetically engineered strain of <i>Lactococcus lactis</i> delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1611-1621.	3.3	65

#	ARTICLE	IF	CITATIONS
181	Bacterial protein signals are associated with Crohn's disease. <i>Gut</i> , 2014, 63, 1566-1577.	12.1	80
182	Probiotics and Antibiotics in IBD. <i>Digestive Diseases</i> , 2014, 32, 10-17.	1.9	43
183	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014, 5, 4675.	12.8	76
184	CD4CD8 ⁺ Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease. <i>PLoS Biology</i> , 2014, 12, e1001833.	5.6	117
185	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 712-720.	3.7	59
186	The Commensal Bacterium <i>Faecalibacterium prausnitzii</i> Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 417-430.	1.9	204
187	Complications and surgery in the inflammatory bowel diseases biological era. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 378-384.	2.3	46
188	Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	1.9	160
189	Ecology and metabolism of the beneficial intestinal commensal bacterium <i>Faecalibacterium prausnitzii</i> . <i>Gut Microbes</i> , 2014, 5, 146-151.	9.8	128
190	Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 819-824.	1.3	28
191	Letter: not the end of the role of anti-viral therapy in ulcerative colitis with cytomegalovirus reactivation – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1247-1248.	3.7	0
192	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	12.1	122
193	Impact of Probiotics on Risk Factors for Cardiovascular Diseases. A Review. <i>Critical Reviews in Food Science and Nutrition</i> , 2014, 54, 175-189.	10.3	75
194	Prevalence and risk factors of <i>Clostridium difficile</i> infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. <i>Digestive and Liver Disease</i> , 2014, 46, 1086-1092.	0.9	40
195	Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 31-44.	1.3	130
196	Crohn's disease of the vulva. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 563-570.	1.3	87
197	P1268 IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE IN CFTR KNOCKOUT MICE. <i>Journal of Hepatology</i> , 2014, 60, S512.	3.7	0
198	Beneficial Effects of Exclusive Enteral Nutrition in Crohn's Disease Are not Mediated by <i>Faecalibacterium prausnitzii</i> . <i>Inflammatory Bowel Diseases</i> , 2014, 20, E18.	1.9	5

#	ARTICLE	IF	CITATIONS
199	Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Patients With Inflammatory Bowel Disease: Presidential Poster. American Journal of Gastroenterology, 2014, 109, S487.	0.4	1
200	Card9 Mediates Intestinal Epithelial Cell Restitution, T-Helper 17 Responses, and Control of Bacterial Infection in Mice. Gastroenterology, 2013, 145, 591-601.e3.	1.3	131
201	Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology, 2013, 16, 255-261.	5.1	829
202	Gastrointestinal manifestations in mastocytosis: A study of 83 patients. Journal of Allergy and Clinical Immunology, 2013, 132, 866-873.e3.	2.9	66
203	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: A retrospective case series. Journal of Allergy and Clinical Immunology, 2013, 132, 997-1000.e4.	2.9	26
204	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, 2013, 62, 531-539.	12.1	663
205	Long-term Outcome of Patients With Crohn's Disease Who Respond to Azathioprine. Clinical Gastroenterology and Hepatology, 2013, 11, 389-394.	4.4	60
206	Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2084-2090.	1.9	48
207	Factors affecting outcomes in Crohn's disease over 15 years. Gut, 2012, 61, 1140-1145.	12.1	108
208	p40phox Expression Regulates Neutrophil Recruitment and Function during the Resolution Phase of Intestinal Inflammation. Journal of Immunology, 2012, 189, 3631-3640.	0.8	46
209	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biology, 2012, 13, R79.	9.6	2,258
210	Crosstalk between the hepatologist and the cardiologist: A future place for the lithocholic acid as a coronary atheroma risk factor?. Hepatology, 2012, 56, 2426-2426.	7.3	17
211	Anti-inflammatory properties of dairy lactobacilli. Inflammatory Bowel Diseases, 2012, 18, 657-666.	1.9	68
212	Current smoking differentially affects blood mononuclear cells from patients with crohn's disease and ulcerative colitis: Relevance to its adverse role in the disease. Inflammatory Bowel Diseases, 2012, 18, 1101-1111.	1.9	40
213	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	1.9	96
214	Colorectal neoplasia in PSC-IBD patients: are times changing?. Liver International, 2012, 32, 175-176.	3.9	1
215	Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterology and Motility, 2012, 24, 513.	3.0	209
216	Clinical, serological and genetic predictors of inflammatory bowel disease course. World Journal of Gastroenterology, 2012, 18, 3806.	3.3	75

#	ARTICLE	IF	CITATIONS
217	How to Identify High-Risk Patients in Inflammatory Bowel Disease?. , 2012, , 713-725.		0
218	Dysbiosis in Inflammatory Bowel Disease: A Link With Antimicrobial Peptides Secretion?. Gastroenterology, 2011, 140, S-328.	1.3	1
219	Air mass pushing the liver. Digestive and Liver Disease, 2011, 43, 1025.	0.9	0
220	Excess Intestinal Lymphoproliferative Disorders in IBD. Gastroenterology, 2011, 140, S-42.	1.3	3
221	Crohn's Disease Associated Dysbiosis as a Predictive Factor of Clinical Relapse: A Microbiological Substudy of the GETAID-STORI Cohort. Gastroenterology, 2011, 140, S-48.	1.3	1
222	Predictors of a 15-Year Non Severe Course in Crohn's Disease. Gastroenterology, 2011, 140, S-777.	1.3	0
223	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Current Opinion in Gastroenterology, 2010, 26, 327-331.	2.3	133
224	Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. International Journal of Food Microbiology, 2010, 144, 35-41.	4.7	117
225	Current Smoking, Not Duration of Remission, Delays Crohn's Disease Relapse Following Azathioprine Withdrawal. Inflammatory Bowel Diseases, 2010, 16, 362-363.	1.9	12
226	Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. Inflammatory Bowel Diseases, 2010, 16, 356-357.	1.9	14
227	Body mass index and disease activity at treatment initiation. Inflammatory Bowel Diseases, 2010, 16, 714-715.	1.9	2
228	Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflammatory Bowel Diseases, 2010, 16, 1247-1253.	1.9	88
229	Sera from patients with Crohn's disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. Innate Immunity, 2010, 16, 381-390.	2.4	13
230	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. Journal of Crohn's and Colitis, 2010, 4, 669-670.	1.3	11
231	Unilateral carotid granulomatous arteritis and Crohn's disease. Revue Neurologique, 2010, 166, 542-546.	1.5	7
232	Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis. American Journal of Gastroenterology, 2010, 105, 2405-2411.	0.4	69
233	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut, 2010, 59, 1363-1368.	12.1	155
234	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. World Journal of Gastroenterology, 2010, 16, 583.	3.3	18

#	ARTICLE	IF	CITATIONS
235	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. <i>Gut</i> , 2009, 58, 1427-1436.	12.1	66
236	Thalidomide as a Treatment for Refractory CGD Colitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1069-1069.	0.4	10
237	Single Immunoglobulin Infusion Can Reverse Hemodynamic Failure Associated With Severe <i>Clostridium difficile</i> Colitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 2649-2650.	0.4	2
238	Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. <i>Gut</i> , 2009, 58, 1218-1225.	12.1	101
239	Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye. <i>Digestive Diseases</i> , 2009, 27, 375-381.	1.9	21
240	Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1449-1451.	1.9	21
241	Effects of light smoking consumption on the clinical course of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 734-741.	1.9	76
242	Low counts of <i>Faecalibacterium prausnitzii</i> in colitis microbiota. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1183-1189.	1.9	1,052
243	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1106-1113.	3.7	72
244	Toll-like receptor 2 is critical for induction of Reg3A expression and intestinal clearance of <i>Yersinia pseudotuberculosis</i> . <i>Gut</i> , 2009, 58, 771-776.	12.1	93
245	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 906-912.	3.3	35
246	Analysis of bacterial bowel communities of IBD patients: What has it revealed?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 858-867.	1.9	193
247	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16731-16736.	7.1	3,581
248	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3497.	3.3	87
249	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. <i>Gut</i> , 2007, 56, 152-154.	12.1	40
250	Pure Ileal Crohn's Disease Without Colonic Involvement After a Long Ileocolonic Anastomosis (Lester) Tj ETQq0 0 0 rgBT /Overlock 1 in a Subset of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 243-244.	1.9	8
251	Temperature Gradient Gel Electrophoresis of Fecal 16S rRNA Reveals Active <i>Escherichia coli</i> in the Microbiota of Patients with Ulcerative Colitis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3172-3177.	3.9	131
252	Specificities of the fecal microbiota in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 106-111.	1.9	373

#	ARTICLE	IF	CITATIONS
253	Renal Cortical Necrosis Related to Paraneoplastic Antiphospholipid Syndrome. American Journal of Kidney Diseases, 2006, 47, 1072-1074.	1.9	6
254	Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoglycoside. Nephrology Dialysis Transplantation, 2004, 19, 1921-1922.	0.7	19
255	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. , 0, .		1
256	Specific gut microbiota taxa as a key source of variability in colitis model. Nature Reviews Gastroenterology and Hepatology, 0, , .	17.8	0